JP2017518372A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017518372A5 JP2017518372A5 JP2017515026A JP2017515026A JP2017518372A5 JP 2017518372 A5 JP2017518372 A5 JP 2017518372A5 JP 2017515026 A JP2017515026 A JP 2017515026A JP 2017515026 A JP2017515026 A JP 2017515026A JP 2017518372 A5 JP2017518372 A5 JP 2017518372A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- composition
- complementary sequence
- guide rna
- ebv genome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 75
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 42
- 108020005004 Guide RNA Proteins 0.000 claims description 38
- 239000013598 vector Substances 0.000 claims description 24
- 210000004027 cell Anatomy 0.000 claims description 17
- 241000700605 Viruses Species 0.000 claims description 16
- 230000003612 virological effect Effects 0.000 claims description 15
- 108091033409 CRISPR Proteins 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 12
- 239000013612 plasmid Substances 0.000 claims description 12
- 230000001105 regulatory effect Effects 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 7
- 102000039446 nucleic acids Human genes 0.000 claims description 7
- 150000007523 nucleic acids Chemical class 0.000 claims description 7
- 239000013603 viral vector Substances 0.000 claims description 6
- 230000010076 replication Effects 0.000 claims description 5
- 229920006317 cationic polymer Polymers 0.000 claims description 3
- 239000002502 liposome Substances 0.000 claims description 3
- 239000002082 metal nanoparticle Substances 0.000 claims description 3
- 239000000693 micelle Substances 0.000 claims description 3
- 239000002105 nanoparticle Substances 0.000 claims description 3
- 239000002073 nanorod Substances 0.000 claims description 3
- 241000701161 unidentified adenovirus Species 0.000 claims description 3
- 241001529453 unidentified herpesvirus Species 0.000 claims description 3
- 241000710929 Alphavirus Species 0.000 claims description 2
- 241000702421 Dependoparvovirus Species 0.000 claims description 2
- 208000032420 Latent Infection Diseases 0.000 claims description 2
- 241000713666 Lentivirus Species 0.000 claims description 2
- 241000700618 Vaccinia virus Species 0.000 claims description 2
- 125000002091 cationic group Chemical group 0.000 claims description 2
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 241001430294 unidentified retrovirus Species 0.000 claims description 2
- 230000000295 complement effect Effects 0.000 claims 38
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 7
- 206010015108 Epstein-Barr virus infection Diseases 0.000 claims 2
- 210000003527 eukaryotic cell Anatomy 0.000 claims 2
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 claims 1
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 claims 1
- -1 cationic lipid Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 101710163270 Nuclease Proteins 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 11
- 229940124597 therapeutic agent Drugs 0.000 description 11
- 241000282414 Homo sapiens Species 0.000 description 5
- 238000010354 CRISPR gene editing Methods 0.000 description 4
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 4
- 208000036142 Viral infection Diseases 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 210000001428 peripheral nervous system Anatomy 0.000 description 2
- 101710092462 Alpha-hemolysin Proteins 0.000 description 1
- 108050006685 Apoptosis regulator BAX Proteins 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 241001302512 Banna virus Species 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 201000003075 Crimean-Congo hemorrhagic fever Diseases 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 241000190708 Guanarito mammarenavirus Species 0.000 description 1
- 241000893570 Hendra henipavirus Species 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 208000005331 Hepatitis D Diseases 0.000 description 1
- 241000724675 Hepatitis E virus Species 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101100325746 Homo sapiens BAK1 gene Proteins 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 241001479210 Human astrovirus Species 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 241000046923 Human bocavirus Species 0.000 description 1
- 241000342334 Human metapneumovirus Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 241000702617 Human parvovirus B19 Species 0.000 description 1
- 241000829111 Human polyomavirus 1 Species 0.000 description 1
- 241000701460 JC polyomavirus Species 0.000 description 1
- 241000712890 Junin mammarenavirus Species 0.000 description 1
- 241000712902 Lassa mammarenavirus Species 0.000 description 1
- 241000712898 Machupo mammarenavirus Species 0.000 description 1
- 241001115401 Marburgvirus Species 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241000526636 Nipah henipavirus Species 0.000 description 1
- 241000714209 Norwalk virus Species 0.000 description 1
- 241000702259 Orbivirus Species 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 241000192617 Sabia mammarenavirus Species 0.000 description 1
- 238000010459 TALEN Methods 0.000 description 1
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 241000710886 West Nile virus Species 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462005395P | 2014-05-30 | 2014-05-30 | |
| US62/005,395 | 2014-05-30 | ||
| US201462029072P | 2014-07-25 | 2014-07-25 | |
| US62/029,072 | 2014-07-25 | ||
| PCT/US2015/033186 WO2015184262A1 (en) | 2014-05-30 | 2015-05-29 | Compositions and methods of delivering treatments for latent viral infections |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017518372A JP2017518372A (ja) | 2017-07-06 |
| JP2017518372A5 true JP2017518372A5 (enExample) | 2018-07-05 |
Family
ID=53366336
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017515026A Pending JP2017518372A (ja) | 2014-05-30 | 2015-05-29 | 潜伏性ウイルス感染用の処置剤を送達するための組成物および方法 |
| JP2017515025A Pending JP2017518075A (ja) | 2014-05-30 | 2015-05-29 | 潜伏性ウイルス感染を処置するための組成物および方法 |
| JP2019205922A Pending JP2020043862A (ja) | 2014-05-30 | 2019-11-14 | 潜伏性ウイルス感染を処置するための組成物および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017515025A Pending JP2017518075A (ja) | 2014-05-30 | 2015-05-29 | 潜伏性ウイルス感染を処置するための組成物および方法 |
| JP2019205922A Pending JP2020043862A (ja) | 2014-05-30 | 2019-11-14 | 潜伏性ウイルス感染を処置するための組成物および方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (7) | US20160060655A1 (enExample) |
| EP (3) | EP3149170A1 (enExample) |
| JP (3) | JP2017518372A (enExample) |
| KR (1) | KR20170005494A (enExample) |
| CN (2) | CN107002094A (enExample) |
| AU (3) | AU2015266776A1 (enExample) |
| BR (1) | BR112016028023A2 (enExample) |
| CA (2) | CA2949713A1 (enExample) |
| SG (1) | SG11201610028TA (enExample) |
| WO (3) | WO2015184262A1 (enExample) |
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10323236B2 (en) | 2011-07-22 | 2019-06-18 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| AU2014207618A1 (en) | 2013-01-16 | 2015-08-06 | Emory University | Cas9-nucleic acid complexes and uses related thereto |
| SI2986729T1 (sl) | 2013-04-16 | 2019-02-28 | Regeneron Pharmaceuticals, Inc. | Ciljana sprememba genoma podgane |
| US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US9925248B2 (en) | 2013-08-29 | 2018-03-27 | Temple University Of The Commonwealth System Of Higher Education | Methods and compositions for RNA-guided treatment of HIV infection |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
| US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
| CN110951779B (zh) | 2013-12-11 | 2024-04-16 | 瑞泽恩制药公司 | 用于靶向修饰基因组的方法和组合物 |
| US11053481B2 (en) | 2013-12-12 | 2021-07-06 | President And Fellows Of Harvard College | Fusions of Cas9 domains and nucleic acid-editing domains |
| JP2017518372A (ja) | 2014-05-30 | 2017-07-06 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 潜伏性ウイルス感染用の処置剤を送達するための組成物および方法 |
| EP4079847A1 (en) | 2014-07-30 | 2022-10-26 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
| BR112017010547A2 (pt) | 2014-11-21 | 2018-02-27 | Regeneron Pharma | métodos para produção de uma modificação bialélica, modificação de um genoma dentro de uma célula, produção de uma geração f0 de um animal não humano e identificação de uma inserção de um inserto de ácido nucleico. |
| KR102763527B1 (ko) | 2014-12-03 | 2025-02-05 | 애질런트 테크놀로지스, 인크. | 화학적 변형을 갖는 가이드 rna |
| US10059940B2 (en) * | 2015-01-27 | 2018-08-28 | Minghong Zhong | Chemically ligated RNAs for CRISPR/Cas9-lgRNA complexes as antiviral therapeutic agents |
| KR102648489B1 (ko) | 2015-04-06 | 2024-03-15 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | Crispr/cas-매개 유전자 조절을 위한 화학적으로 변형된 가이드 rna |
| GB2543873A (en) * | 2015-05-29 | 2017-05-03 | Agenovir Corp | Compositions and methods for cell targeted HPV treatment |
| US20160346362A1 (en) * | 2015-05-29 | 2016-12-01 | Agenovir Corporation | Methods and compositions for treating cytomegalovirus infections |
| US20160348074A1 (en) * | 2015-05-29 | 2016-12-01 | Agenovir Corporation | Methods and compositions for treating cells for transplant |
| US10117911B2 (en) | 2015-05-29 | 2018-11-06 | Agenovir Corporation | Compositions and methods to treat herpes simplex virus infections |
| EP3355954A4 (en) * | 2015-09-29 | 2020-01-08 | Agenovir Corporation | METHODS AND COMPOSITIONS OF ADMINISTRATION |
| WO2017068077A1 (en) | 2015-10-20 | 2017-04-27 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Methods and products for genetic engineering |
| IL294014B2 (en) | 2015-10-23 | 2024-07-01 | Harvard College | Nucleobase editors and uses thereof |
| CA3006305A1 (en) | 2015-12-09 | 2017-06-15 | Excision Biotherapeutics, Inc. | Gene editing methods and compositions for eliminating risk of jc virus activation and pml (progressive multifocal leukoencephalopathy) during immunosuppressive therapy |
| CN108603196A (zh) * | 2016-01-25 | 2018-09-28 | 酶切生物技术公司 | Rna向导的对人类jc病毒和其他多瘤病毒的根除 |
| AU2017211062A1 (en) * | 2016-01-25 | 2018-06-07 | Excision Biotherapeutics | Methods and compositions for RNA-guided treatment of HIV infection |
| US20170246260A1 (en) * | 2016-02-25 | 2017-08-31 | Agenovir Corporation | Modified antiviral nuclease |
| CA3015353A1 (en) * | 2016-02-25 | 2017-08-31 | Agenovir Corporation | Viral and oncoviral nuclease treatment |
| US11299751B2 (en) | 2016-04-29 | 2022-04-12 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| WO2017192172A1 (en) * | 2016-05-05 | 2017-11-09 | Temple University - Of The Commonwealth System Of Higher Education | Rna guided eradication of varicella zoster virus |
| EP3455347A4 (en) * | 2016-05-10 | 2019-10-02 | United States Government as Represented by The Department of Veterans Affairs | LENTIVIRAL DELIVERY OF CRISPR / CAS CONSTRUCTS COLUMNS ESSENTIAL GENES FOR HIV-1 INFECTION AND REPLICATION |
| IL262888B1 (en) | 2016-05-20 | 2025-10-01 | Regeneron Pharma | Methods for breaking immunological tolerance using multiple guide RNAs |
| AU2017273713A1 (en) * | 2016-06-01 | 2018-10-25 | Excision Biotherapeutics, Inc. | Compositions and methods of treatment for lytic and lysogenic viruses |
| US10767175B2 (en) | 2016-06-08 | 2020-09-08 | Agilent Technologies, Inc. | High specificity genome editing using chemically modified guide RNAs |
| CA3027428A1 (en) * | 2016-06-14 | 2017-12-21 | Regents Of The University Of Minnesota | Genetically modified cells, tissues, and organs for treating disease |
| WO2018027078A1 (en) | 2016-08-03 | 2018-02-08 | President And Fellows Of Harard College | Adenosine nucleobase editors and uses thereof |
| US11661590B2 (en) | 2016-08-09 | 2023-05-30 | President And Fellows Of Harvard College | Programmable CAS9-recombinase fusion proteins and uses thereof |
| US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| US11801374B2 (en) * | 2016-09-02 | 2023-10-31 | The General Hospital Corporation | Methods and systems for non-contact construction of an internal structure |
| US10662416B2 (en) | 2016-10-14 | 2020-05-26 | Precision Biosciences, Inc. | Engineered meganucleases specific for recognition sequences in the hepatitis B virus genome |
| SG11201903089RA (en) | 2016-10-14 | 2019-05-30 | Harvard College | Aav delivery of nucleobase editors |
| US11584931B2 (en) | 2016-12-14 | 2023-02-21 | The J. David Gladstone Institutes | Methods and compositions for generating a deletion library and for identifying a defective interfering particle (DIP) |
| CN106729753A (zh) * | 2016-12-16 | 2017-05-31 | 谭旭 | 抗乙型肝炎病毒的递送系统和生物制剂 |
| WO2018118586A1 (en) * | 2016-12-22 | 2018-06-28 | Agenovir Corporation | Antiviral/endogenous combination therapy |
| WO2018118587A1 (en) * | 2016-12-22 | 2018-06-28 | Agenovir Corporation | Modified polynucleotides for antiviral therapy |
| US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
| JP2020513783A (ja) * | 2017-01-18 | 2020-05-21 | エクシジョン バイオセラピューティクス インコーポレイテッド | Ｃｒｉｓｐｒ |
| US20190071673A1 (en) * | 2017-01-18 | 2019-03-07 | Thomas Malcolm | CRISPRs WITH IMPROVED SPECIFICITY |
| JP2020505390A (ja) * | 2017-01-26 | 2020-02-20 | エクシジョン バイオセラピューティクス インコーポレイテッド | Ｃｒｉｓｐｒ治療薬を送達するためのウイルスベクターとしてのレンチウイルスおよび非組み込みレンチウイルス |
| EP3592381A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Cancer vaccine |
| EP3592853A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Suppression of pain by gene editing |
| CN110914310A (zh) | 2017-03-10 | 2020-03-24 | 哈佛大学的校长及成员们 | 胞嘧啶至鸟嘌呤碱基编辑器 |
| GB2575930A (en) | 2017-03-23 | 2020-01-29 | Harvard College | Nucleobase editors comprising nucleic acid programmable DNA binding proteins |
| WO2018209320A1 (en) | 2017-05-12 | 2018-11-15 | President And Fellows Of Harvard College | Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation |
| EP3635121A1 (en) * | 2017-06-02 | 2020-04-15 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Viral vector combining gene therapy and genome editing approaches for gene therapy of genetic disorders |
| US11732274B2 (en) | 2017-07-28 | 2023-08-22 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE) |
| AU2018320849A1 (en) * | 2017-08-25 | 2020-03-05 | Ovid Therapeutics Inc. | Recombinant adeno-associated vectors |
| EP3676376B1 (en) | 2017-08-30 | 2025-01-15 | President and Fellows of Harvard College | High efficiency base editors comprising gam |
| WO2019079347A1 (en) | 2017-10-16 | 2019-04-25 | The Broad Institute, Inc. | USES OF BASIC EDITORS ADENOSINE |
| WO2019118949A1 (en) | 2017-12-15 | 2019-06-20 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| TW201945388A (zh) | 2018-04-12 | 2019-12-01 | 美商精密生物科學公司 | 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶 |
| JP7399876B2 (ja) * | 2018-04-16 | 2023-12-18 | ジョージア テック リサーチ コーポレーション | 病態治療のためのＲＮＡエディターのｍＲＮＡ駆動型発現 |
| WO2019226953A1 (en) | 2018-05-23 | 2019-11-28 | The Broad Institute, Inc. | Base editors and uses thereof |
| WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| CN109943563A (zh) * | 2019-03-08 | 2019-06-28 | 内蒙古大学 | CRISPR-Cas9系统介导的狂犬病病毒基因组敲除的方法 |
| DE112020001342T5 (de) | 2019-03-19 | 2022-01-13 | President and Fellows of Harvard College | Verfahren und Zusammensetzungen zum Editing von Nukleotidsequenzen |
| WO2020214842A1 (en) | 2019-04-17 | 2020-10-22 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| EP3981002A4 (en) * | 2019-06-06 | 2023-08-09 | Tata Consultancy Services Limited | METHOD AND SYSTEM FOR IDENTIFICATION OF TARGET SITES IN PROTEIN-CODING REGIONS FOR COMBATING PATHOGENS |
| CN112168808B (zh) * | 2019-07-02 | 2023-01-24 | 深圳市第二人民医院 | 一种基于crispr的细胞核靶向药物递送系统 |
| WO2021072328A1 (en) | 2019-10-10 | 2021-04-15 | The Broad Institute, Inc. | Methods and compositions for prime editing rna |
| FI4069729T3 (fi) | 2019-12-06 | 2025-04-01 | Prec Biosciences Inc | Optimoidut muokatut meganukleaasit, joilla on spesifisyys tunnistussekvenssiä varten hepatiitti b -virusgenomissa |
| GB2614813B (en) | 2020-05-08 | 2025-05-07 | Harvard College | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
| CN112795696A (zh) * | 2020-12-31 | 2021-05-14 | 北京思尔成生物技术有限公司 | 乙型肝炎病毒pgRNA芯片数字PCR绝对定量检测试剂盒及方法 |
| WO2022261150A2 (en) | 2021-06-09 | 2022-12-15 | Scribe Therapeutics Inc. | Particle delivery systems |
| KR20240055811A (ko) | 2021-09-10 | 2024-04-29 | 애질런트 테크놀로지스, 인크. | 프라임 편집을 위한 화학적 변형을 갖는 가이드 rna |
| CN114196556B (zh) * | 2021-12-31 | 2023-08-01 | 重庆大学 | 一种高毒力蝗绿僵菌菌株及其构建方法 |
| WO2023221937A1 (zh) * | 2022-05-16 | 2023-11-23 | 上海行深生物科技有限公司 | 递送自复制rna分子的方法 |
| AU2024270764A1 (en) | 2023-05-15 | 2025-12-04 | Nchroma Bio, Inc. | Compositions and methods for epigenetic regulation of hbv gene expression |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1003131A (en) * | 1910-08-17 | 1911-09-12 | Leonard F Bellingrath | Valve operating and indicating mechanism. |
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US5208036A (en) | 1985-01-07 | 1993-05-04 | Syntex (U.S.A.) Inc. | N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| WO1991017424A1 (en) | 1990-05-03 | 1991-11-14 | Vical, Inc. | Intracellular delivery of biologically active substances by means of self-assembling lipid complexes |
| US5580571A (en) | 1991-10-15 | 1996-12-03 | Hostetler; Karl Y. | Nucleoside analogues |
| SE9200951D0 (sv) | 1992-03-27 | 1992-03-27 | Kabi Pharmacia Ab | Pharmaceutical composition containing a defined lipid system |
| US5487994A (en) | 1992-04-03 | 1996-01-30 | The Johns Hopkins University | Insertion and deletion mutants of FokI restriction endonuclease |
| US5436150A (en) | 1992-04-03 | 1995-07-25 | The Johns Hopkins University | Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease |
| US5356802A (en) | 1992-04-03 | 1994-10-18 | The Johns Hopkins University | Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease |
| EP0642589A4 (en) * | 1992-05-11 | 1997-05-21 | Ribozyme Pharm Inc | METHOD AND REAGENT TO INHIBIT VIRAL REPLICATION. |
| JPH09500013A (ja) | 1993-06-01 | 1997-01-07 | ライフ・テクノロジーズ・インコーポレイテッド | カチオン性脂質による遺伝子免疫 |
| US6242568B1 (en) | 1994-01-18 | 2001-06-05 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
| US6140466A (en) | 1994-01-18 | 2000-10-31 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
| USRE39229E1 (en) | 1994-08-20 | 2006-08-08 | Gendaq Limited | Binding proteins for recognition of DNA |
| US5789538A (en) | 1995-02-03 | 1998-08-04 | Massachusetts Institute Of Technology | Zinc finger proteins with high affinity new DNA binding specificities |
| US5925523A (en) | 1996-08-23 | 1999-07-20 | President & Fellows Of Harvard College | Intraction trap assay, reagents and uses thereof |
| US6410248B1 (en) | 1998-01-30 | 2002-06-25 | Massachusetts Institute Of Technology | General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites |
| US6383481B1 (en) | 1998-03-30 | 2002-05-07 | Japan Immunoresearch Laboratories Co., Ltd. | Method for transplantation of hemopoietic stem cells |
| US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
| US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| EP1233781A1 (en) | 1999-11-24 | 2002-08-28 | Oklahoma Medical Research Foundation | Assays and therapies for latent viral infection |
| AU2003270823A1 (en) * | 2002-09-19 | 2004-04-08 | Johns Hopkins University School Of Medicine | Cancer immunotherapy with a viral antigen-defined, immunomodulator-secreting cell vaccine |
| US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| US8409861B2 (en) | 2003-08-08 | 2013-04-02 | Sangamo Biosciences, Inc. | Targeted deletion of cellular DNA sequences |
| CN101144817B (zh) * | 2003-08-20 | 2011-10-05 | 香港神农有限公司 | 一种eb病毒蛋白酶联免疫吸附诊断试剂盒及其制备方法 |
| US20070275010A1 (en) * | 2003-09-18 | 2007-11-29 | Mark Feinberg | Mva Vaccines |
| ES2525684T3 (es) | 2004-12-29 | 2014-12-29 | Hadasit Medical Research Services And Development Ltd. | Sistemas de cultivo de células madre |
| US8021867B2 (en) * | 2005-10-18 | 2011-09-20 | Duke University | Rationally-designed meganucleases with altered sequence specificity and DNA-binding affinity |
| US20070196389A1 (en) * | 2005-11-18 | 2007-08-23 | The Ohio State University Research Foundation | Viral gene products and methods for vaccination to prevent viral associated diseases |
| GB0526211D0 (en) | 2005-12-22 | 2006-02-01 | Oxford Biomedica Ltd | Viral vectors |
| WO2007139898A2 (en) | 2006-05-25 | 2007-12-06 | Sangamo Biosciences, Inc. | Variant foki cleavage half-domains |
| US8481506B2 (en) * | 2006-12-05 | 2013-07-09 | Rosetta Genomics, Ltd. | Nucleic acids involved in viral infection |
| US20100076057A1 (en) | 2008-09-23 | 2010-03-25 | Northwestern University | TARGET DNA INTERFERENCE WITH crRNA |
| US20110023144A1 (en) | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genomic editing of genes involved in amyotrophyic lateral sclerosis disease |
| CN101880649B (zh) | 2009-05-05 | 2012-09-05 | 中国福利会国际和平妇幼保健院 | 一种干细胞培养方法 |
| US10238734B2 (en) * | 2010-03-23 | 2019-03-26 | The Regents Of The University Of California | Compositions and methods for self-adjuvanting vaccines against microbes and tumors |
| US9637739B2 (en) | 2012-03-20 | 2017-05-02 | Vilnius University | RNA-directed DNA cleavage by the Cas9-crRNA complex |
| WO2013141680A1 (en) | 2012-03-20 | 2013-09-26 | Vilnius University | RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX |
| CN103361328B (zh) * | 2012-03-30 | 2017-08-18 | 复旦大学 | 介导整合的hiv‑1前病毒基因敲除的锌指核酸内切酶及其制法和应用 |
| WO2013176772A1 (en) | 2012-05-25 | 2013-11-28 | The Regents Of The University Of California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
| WO2013188037A2 (en) | 2012-06-11 | 2013-12-19 | Agilent Technologies, Inc | Method of adaptor-dimer subtraction using a crispr cas6 protein |
| US20150315576A1 (en) * | 2012-11-01 | 2015-11-05 | Massachusetts Institute Of Technology | Genetic device for the controlled destruction of dna |
| WO2014093479A1 (en) | 2012-12-11 | 2014-06-19 | Montana State University | Crispr (clustered regularly interspaced short palindromic repeats) rna-guided control of gene regulation |
| CN105209621B (zh) | 2012-12-12 | 2021-05-25 | 布罗德研究所有限公司 | 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化 |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| IL307735A (en) | 2012-12-12 | 2023-12-01 | Broad Inst Inc | Systems engineering, methods and optimal guiding components for sequence manipulation |
| PL2931898T3 (pl) | 2012-12-12 | 2016-09-30 | Le Cong | Projektowanie i optymalizacja systemów, sposoby i kompozycje do manipulacji sekwencją z domenami funkcjonalnymi |
| DK2921557T3 (en) | 2012-12-12 | 2016-11-07 | Broad Inst Inc | Design of systems, methods and optimized sequence manipulation guide compositions |
| AU2013359199C1 (en) * | 2012-12-12 | 2021-06-17 | Massachusetts Institute Of Technology | Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications |
| EP4481048A3 (en) | 2012-12-17 | 2025-02-26 | President and Fellows of Harvard College | Rna-guided human genome engineering |
| AU2014207618A1 (en) | 2013-01-16 | 2015-08-06 | Emory University | Cas9-nucleic acid complexes and uses related thereto |
| US10660943B2 (en) | 2013-02-07 | 2020-05-26 | The Rockefeller University | Sequence specific antimicrobials |
| US10612043B2 (en) | 2013-03-09 | 2020-04-07 | Agilent Technologies, Inc. | Methods of in vivo engineering of large sequences using multiple CRISPR/cas selections of recombineering events |
| ES2901396T3 (es) | 2013-03-14 | 2022-03-22 | Caribou Biosciences Inc | Composiciones y métodos de ácidos nucleicos dirigidos a ácido nucleico |
| US20140349400A1 (en) | 2013-03-15 | 2014-11-27 | Massachusetts Institute Of Technology | Programmable Modification of DNA |
| AU2014228981B2 (en) | 2013-03-15 | 2019-11-28 | The General Hospital Corporation | Using truncated guide RNAs (tru-gRNAs) to increase specificity for RNA-guided genome editing |
| US20140273230A1 (en) | 2013-03-15 | 2014-09-18 | Sigma-Aldrich Co., Llc | Crispr-based genome modification and regulation |
| US9234213B2 (en) | 2013-03-15 | 2016-01-12 | System Biosciences, Llc | Compositions and methods directed to CRISPR/Cas genomic engineering systems |
| WO2014165349A1 (en) | 2013-04-04 | 2014-10-09 | Trustees Of Dartmouth College | Compositions and methods for in vivo excision of hiv-1 proviral dna |
| WO2014172470A2 (en) | 2013-04-16 | 2014-10-23 | Whitehead Institute For Biomedical Research | Methods of mutating, modifying or modulating nucleic acid in a cell or nonhuman mammal |
| WO2014186585A2 (en) | 2013-05-15 | 2014-11-20 | Sangamo Biosciences, Inc. | Methods and compositions for treatment of a genetic condition |
| US9873907B2 (en) | 2013-05-29 | 2018-01-23 | Agilent Technologies, Inc. | Method for fragmenting genomic DNA using CAS9 |
| IL303973A (en) | 2013-07-09 | 2023-08-01 | Harvard College | Multiplexed RNA-guided genome engineering |
| US9663782B2 (en) | 2013-07-19 | 2017-05-30 | Larix Bioscience Llc | Methods and compositions for producing double allele knock outs |
| US9925248B2 (en) | 2013-08-29 | 2018-03-27 | Temple University Of The Commonwealth System Of Higher Education | Methods and compositions for RNA-guided treatment of HIV infection |
| DK3041498T3 (da) | 2013-09-05 | 2022-05-09 | Massachusetts Inst Technology | Afstemning af mikrobielle populationer med programmerbare nukleaser |
| EP4372090A3 (en) | 2013-11-07 | 2024-08-07 | Editas Medicine, Inc. | Crispr-related methods and compositions with governing grnas |
| EP3080261B1 (en) * | 2013-12-12 | 2019-05-22 | The Broad Institute, Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for hbv and viral diseases and disorders |
| EP3470089A1 (en) | 2013-12-12 | 2019-04-17 | The Broad Institute Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components |
| US9476065B2 (en) | 2013-12-19 | 2016-10-25 | Amyris, Inc. | Methods for genomic integration |
| CA2940084A1 (en) | 2014-02-18 | 2015-08-27 | Duke University | Compositions for the inactivation of virus replication and methods of making and using the same |
| US10507232B2 (en) | 2014-04-02 | 2019-12-17 | University Of Florida Research Foundation, Incorporated | Materials and methods for the treatment of latent viral infection |
| CN103911376B (zh) | 2014-04-03 | 2017-02-15 | 黄行许 | CRISPR‑Cas9靶向敲除乙肝病毒cccDNA及其特异性sgRNA |
| JP2017518372A (ja) | 2014-05-30 | 2017-07-06 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 潜伏性ウイルス感染用の処置剤を送達するための組成物および方法 |
-
2015
- 2015-05-29 JP JP2017515026A patent/JP2017518372A/ja active Pending
- 2015-05-29 EP EP15729007.3A patent/EP3149170A1/en not_active Withdrawn
- 2015-05-29 US US14/725,888 patent/US20160060655A1/en not_active Abandoned
- 2015-05-29 WO PCT/US2015/033186 patent/WO2015184262A1/en not_active Ceased
- 2015-05-29 CA CA2949713A patent/CA2949713A1/en not_active Abandoned
- 2015-05-29 WO PCT/US2015/033180 patent/WO2015184259A1/en not_active Ceased
- 2015-05-29 KR KR1020167036734A patent/KR20170005494A/ko not_active Withdrawn
- 2015-05-29 AU AU2015266776A patent/AU2015266776A1/en not_active Abandoned
- 2015-05-29 CA CA2949710A patent/CA2949710A1/en not_active Abandoned
- 2015-05-29 AU AU2015266767A patent/AU2015266767A1/en not_active Abandoned
- 2015-05-29 BR BR112016028023A patent/BR112016028023A2/pt not_active Application Discontinuation
- 2015-05-29 CN CN201580028992.1A patent/CN107002094A/zh active Pending
- 2015-05-29 EP EP15727838.3A patent/EP3149169A1/en not_active Withdrawn
- 2015-05-29 SG SG11201610028TA patent/SG11201610028TA/en unknown
- 2015-05-29 CN CN201580029041.6A patent/CN106574256A/zh active Pending
- 2015-05-29 AU AU2015266770A patent/AU2015266770A1/en not_active Abandoned
- 2015-05-29 WO PCT/US2015/033199 patent/WO2015184268A1/en not_active Ceased
- 2015-05-29 US US14/725,943 patent/US10066241B2/en not_active Expired - Fee Related
- 2015-05-29 EP EP15729008.1A patent/EP3149171A1/en not_active Withdrawn
- 2015-05-29 JP JP2017515025A patent/JP2017518075A/ja active Pending
- 2015-07-02 US US14/790,748 patent/US9487802B2/en not_active Expired - Fee Related
-
2016
- 2016-11-28 US US15/362,519 patent/US20170182190A1/en not_active Abandoned
-
2018
- 2018-01-23 US US15/877,996 patent/US20190010518A1/en not_active Abandoned
- 2018-03-20 US US15/926,688 patent/US20190032090A1/en not_active Abandoned
- 2018-07-26 US US16/046,083 patent/US20190185882A1/en not_active Abandoned
-
2019
- 2019-11-14 JP JP2019205922A patent/JP2020043862A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017518372A5 (enExample) | ||
| JP2017518075A5 (enExample) | ||
| US11273209B2 (en) | Methods and compositions for RNA-guided treatment of HIV infection | |
| JP7522088B2 (ja) | 単純ヘルペス１型および他の関連するヘルペスウイルスのｒｎａガイド除去 | |
| AU2017219605B2 (en) | Excision of retroviral nucleic acid sequences | |
| US20180207243A1 (en) | Methods and compositions for rna-guided treatment of hiv infection | |
| JP2012509340A5 (enExample) | ||
| WO2017132112A1 (en) | Methods and compositions for rna-guided treatment of hiv infection | |
| KR20170005494A (ko) | 잠복 바이러스 감염에 대한 치료제를 전달하는 조성물 및 방법 | |
| WO2009012143A3 (en) | Virus derived antimicrobial peptides | |
| JP2016074727A5 (enExample) | ||
| Azevedo-Pereira et al. | Inhibition of HIV replication by host cellular factors | |
| De Clercq | Status presens of antiviral drugs and strategies: Part I: DNA viruses and retroviruses | |
| Falqui | Development of poxvirus-derived vectors to analyze novel ISG15 functions | |
| JP2017504331A5 (enExample) | ||
| WO2022256516A2 (en) | Gene editing therapy for hiv infection via dual targeting of hiv genome and ccr5 | |
| WO2005100383A8 (en) | Novel hiv+ infected cells targeting retroviral vectors and uses thereof for treatment of hiv infection | |
| HK40000290A (en) | Excision of retroviral nucleic acid sequences | |
| HK1253882B (en) | Methods and compositions for rna-guided treatment of hiv infection | |
| JP2010248179A (ja) | 医薬組成物 |